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Abstract
At the plenary session of the 2008 annual meeting of the American Society of Clinical Oncology,
updated results were presented from a large randomized phase III trial comparing adjuvant
radiation therapy (RT) and one cycle of Carboplatin for the adjuvant treatment of Stage I
seminoma. Results of this Medical Research Council (MRC) trial led its investigators to conclude
that one cycle of carboplatin was equivalent in safety and efficacy and less toxic than RT. In this
editorial, the trial's design, statistics, toxicity, and length of follow-up are discussed within the
context of historical treatments of this disease. With a 1.3% increase in relapse rate (5.3% with
carboplatin vs. 4.0% with radiation), a 3% or greater increase in relapse rate could not be excluded,
the primary endpoint of the study. A decrease in second testicular germ cell tumors was observed,
but was equivalent to the increase in relapse rate. Acute toxicity was generally less with carboplatin.
However, the extent of late toxicity, including late second neoplasms, cannot be evaluated because
of the short median follow-up. Carboplatin is not yet a standard of care. Surveillance-based
strategies, including risk-adapted policies that limit RT to patients with the greatest likelihood of
relapse remain prudent at this time.
At the plenary session of the 2008 annual meeting of the
American Society of Clinical Oncology (ASCO), the
updated results[1] of a large phase 3 randomized trial con-
ducted by the Medical Research Council (MRC) compar-
ing a single dose of carboplatin (AUC = 7) with radiation
therapy (RT) as adjuvant treatment of patients with stage
I seminoma were reported. The authors had previously
published this trial in 2005, [2] at which time a major crit-
icism was the short median follow-up time of 4 years.
Now, with a median follow-up of 6.5 years, 5-year relapse
rates of 5.3% for carboplatin and 4% for radiation were
reported, with a significantly reduced frequency of con-
tralateral primary testicular tumors (0.3% vs. 1.7%) and
dyspepsia, and a greater ability to work 4 weeks after start-
ing treatment in the carboplatin arm.[1] The authors
stated that the 1.3% difference in absolute relapse rates
between the 2 arms with the sample size of 1477 can reli-
ably exclude ≥ 3.6% higher relapse rate with carboplatin
as compared to RT. The authors concluded that "...with
mature follow-up, one course of carboplatin is safe, less
acutely toxic, and as effective as radiation for stage I sem-
inoma".[1]
Based on these results, should carboplatin now be offered
to all patients with stage I seminoma? In order to answer
this question, it is necessary to review expected outcomes,
the trial's design and statistics, and the toxicity and post-
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therapy follow-up necessary for the available treatment
options.
Stage I seminoma is the most common single stage/histol-
ogy of testicular cancer, comprising up to 80% of semino-
mas and 40% of all testicular cancers.[3] Since
surveillance (with treatment upon relapse) and adjuvant
RT each achieve an overall survival approaching 100%,
treatment toxicity, quality of life, and relative intensity of
follow-up have dominated discussions of the optimal
approach rather than efficacy. Any new treatment option
must maintain the negligible disease-specific mortality
rate without increasing the frequency of serious adverse
events or intensifying follow-up requirements.
The MRC trial was designed to exclude a > 3% increase in
relapse rate with carboplatin. The 90% confidence interval
for difference in relapse rates was -0.7% to 3.5%, above
the predetermined 3% mark. Hence, the study did not
meet its primary endpoint. Put differently, with a relapse
rate of about 4%, 40/1000 RT patients will relapse and the
MRC trial cannot exclude a relapse frequency of > 70/
1000 with carboplatin. Moreover, a non-inferiority design
is not the same as equivalence, which requires a much
larger number of patients. In addition, while the 1.4%
decrease in contralateral testicular primaries with carbopl-
atin was statistically significant, it may not be clinically
meaningful since it is offset by the 1.3% increase in
relapses.
Relapse site is an important consideration. Like surveil-
lance, the majority of relapses after carboplatin occur in
the retroperitoneum requiring abdominopelvic CT scans
at regular intervals. In contrast, relapses after RT are
almost exclusively outside the retroperitoneum (usually
thoracic), making such testing unnecessary. The dose of
radiation sustained with CT imaging may not be trivial;
indeed, a recent publication proposed that such doses
could increase the risk of developing a secondary malig-
nancy.[4] The need for post-treatment imaging also
requires increased patient compliance compared with RT.
Late toxicity must be also considered. RT, once the stand-
ard of care, has recently been shown to significantly
increase the risk of secondary malignancies. Two large
recent studies show that the risk of secondary cancers is
about double that of age-matched controls.[5,6] At partic-
ular risk are the 4% of patients who relapse after RT and
subsequently require chemotherapy; use of both modali-
ties confers a 3-fold higher risk of developing a secondary
malignancy and also significantly increases the rate of cor-
onary disease.[5,6] These risk differentials only begin to
emerge after 15 years of follow-up.
Therefore, we feel that 6.5 years median followup (only
25% followed ≥ 8 years) is insufficient to assess the fre-
quency of significant long-term toxicity with carboplatin.
This concern is supported by the fact that, to date, a very
low frequency of secondary malignancies has been
observed in the MRC study with no appreciable difference
between the RT and carboplatin arms (1.1% vs. 0.9%).
Like RT, chemotherapy (in particular, high-dose carbopl-
atin and standard-dose cisplatin) has been associated with
secondary malignancies and cardiovascular disease. [5-7]
Whether one dose of carboplatin AUC = 7 might lead to
the same or different frequency of late toxicity as historical
platinum therapies is unknown, but the lack of long-term
data should not be interpreted as proof of safety. While it
is encouraging that a recent report[8] noted no increase in
deaths, cardiovascular disease, or secondary malignancies
after 1 or 2 cycles of carboplatin for Stage I seminoma
compared with age-matched controls, the number of
patients was small (N = 199) and the median follow-up
was still < 10 years.
What about surveillance? Surveillance has become
increasingly recommended as the association between RT
and second malignancy has emerged. A universal adju-
vant approach (either RT or carboplatin) subjects 85%–
90% of patients to treatment unnecessarily (80–85%
patients would be cured with surgery alone and 4% will
relapse despite RT). The main concern with surveillance is
patient compliance with follow-up. A recent report noted
that 21% of seminoma patients on surveillance were lost
to follow-up after a median of 5.5 years.[9] At least 5% of
relapses occur after five years, suggesting that non-compli-
ant patients will present with more advanced disease,
need more intensive treatment, and experience worse
overall outcomes.[10] Finally, the incidence of late
relapses after carboplatin remains unknown and might be
a concern due to inferior efficacy compared with cisplatin
in the metastatic setting.[11,12]
What about a risk-adapted approach? Unfortunately, risk
factors for relapse in stage I seminoma have been difficult
to identify and validate. Combining 3 surveillance series,
Warde and colleagues found tumor size > 4 cm and rete
testis involvement to predict relapse (risk 12% for patients
with 0, 16% with 1, and 32% with both features)[13] but
these factors have not been independently validated. Val-
devenito reported that size > 6 cm and rete testis invasion
were significant risk factors.[14] The Spanish Germ Cell
Cancer Cooperative Group (SGCCCG) was the first to
study a risk-adapted strategy, treating pT1 patients with
surveillance and pT2 patients with 2 cycles of carbopla-
tin.[15] Since tumor size and rete testis involvement were
not criteria for stratification, their correlation with relapse
could be assessed in the surveillance arm. However, only
rete testis invasion had prognostic value.[15] In a secondJournal of Hematology & Oncology 2008, 1:22 http://www.jhoonline.org/content/1/1/22
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risk-adapted study, these same authors stratified patients
based on rete testis invasion and tumor size > 4 cm;
patients with neither factor were observed while the
remainder received 2 cycles of adjuvant carboplatin. The
relapse rate was 3.3% with chemotherapy and 6% with
surveillance, demonstrating the feasibility of a risk-
adapted approach.[16] One concern from the latter trial is
the lack of data regarding long-term toxicity and relapse
with carboplatin.
So, what should you recommend to the next patient you
see with Stage I seminoma? The advantages and disadvan-
tages of each approach should always be carefully dis-
cussed with patients to enable informed decisions.
However, we believe that an active surveillance strategy
remains the most appropriate management policy, either
observing all patients or limiting RT to those most at risk
for relapse. Patients must be able to comply with follow-
up and handle the psychological burden of not receiving
active treatment.
We agree with others[16] that ideal practice would use a
validated risk-adapted approach similar to that employed
for stage IB nonseminomatous germ cell tumors, thus lim-
iting intervention to the patients with the highest risk of
relapse. Employing the international meta-analysis[13]
and the Spanish prospective study[16] as a treatment
guide, the use of size > 4 cm and rete testis involvement as
clinical features identified a high-risk population for
whom clinical intervention over surveillance was favored.
Approximately 16% of Stage I seminoma patients[16] will
fall into this group with an expected relapse rate of 32%
[13] if untreated. In contrast, patients with neither of
these factors had a relapse rate of only 6% in the SGCCCG
trial.[16] Using RT only for the highest risk patients can
avoid immediate treatment (and potentially unnecessary
toxicity) in 84% of men exclusive of non-compliant
patients or those who can not psychologically tolerate sur-
veillance. We view carboplatin as a non-standard alterna-
tive when radiation and surveillance are contraindicated.
To eliminate the controversy over treatment for stage I
seminoma, risk factors for relapse should be further
refined; clinical factors such as age[13,16], pre-orchiec-
tomy HCG[16] and microarray signatures may be of ben-
efit in identifying high risk patients. Our approach at
Memorial Sloan-Kettering Cancer Center utilizes a risk-
adapted approach, recommending RT if the primary
tumor is > 4 cm AND rete testis invasion is present, with a
research emphasis on identifying clinical and biological
factors that can refine high risk criteria. Collaborative
efforts to validate high risk features prospectively will be
essential to optimizing our ability to identify seminoma
patients warranting immediate intervention.
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